The UK’s looming care home shortfall is as unsurprising as the maths is inescapable; the UK’s 65+ population is set to grow by more than 25% by 2035 and the 85+ cohort by roughly 50% over the same period (ONS). Yet both built capacity and the development pipeline remain stubbornly thin. Recent Knight Frank analysis warns that net new supply is minimal as current development barely replaces obsolete stock.
With a net increase of just 86 beds in 2024 (source: Knight Frank), we are now facing a structural deficit measured in tens of thousands of beds, with some commentators forecasting a potential shortfall of almost 100,000 beds by 2033.
This issue can be explained in part by the rapid obsolescence of the UK care home stock versus the sluggish pace of delivery of new homes; the demographic trend does of course compound the problem further. So far, pretty much conventional thinking – but this is typically as far as the thinking seems to go. Orthodoxy would suggest imminent strong inflows of capital to reset the supply / demand imbalance. As this doesn’t yet appear to be the case, we can only assume that either the imbalance is illusory or there are other factors at play which warrant further investigation.
Care home development faces similar headwinds to more conventional real estate development: scarcity of land, planning bottle necks and rising construction costs are as much as feature of the care home development market as any other. But where care differs as an operational asset class is in its requirement for specialist management skills, compliance with stringent CQC regulation, high staffing ratios and long‑term operational commitment. That regulatory and operating overlay raises barriers of entry well above those for conventional real estate and deters mainstream developers and investors.
This operational landscape is also complex – ownership and operation of care homes is fragmented, and the top five operators account for only about 13.1% of beds (source: Care England). With few nationally scaled, balance‑sheet‑strong providers, the industry lacks the institutional capacity to underwrite sustained large‑scale development. The obvious policy lever is consolidation or aggregation - but that presents its own risks and requires careful regulation.
Capital is increasingly available as evidenced by the arrival of global REITs and healthcare investors like Welltower in the UK, yet investor caution persists. Knight Frank notes rising investor selectivity amid construction cost inflation, higher borrowing rates and regulatory scrutiny; yields must balance social purpose with commercial return. Meanwhile, public policy responses remain hesitant. Care England has repeatedly called for long‑term funding clarity and incentives to unlock private capital and stimulate specialist development.
Solving the shortage requires a coordinated package: long‑term funding commitments, planning de‑risking for specialist sites, incentives to attract experienced developers/operators, and workforce investment. The market understands the scale of the problem; what is lacking is the political and financial will to remove the barriers. Without rapid, joined‑up action the UK runs the risk of remaining structurally under‑bedded for decades.